IL154879A0 - Factor vii glycoforms - Google Patents
Factor vii glycoformsInfo
- Publication number
- IL154879A0 IL154879A0 IL15487901A IL15487901A IL154879A0 IL 154879 A0 IL154879 A0 IL 154879A0 IL 15487901 A IL15487901 A IL 15487901A IL 15487901 A IL15487901 A IL 15487901A IL 154879 A0 IL154879 A0 IL 154879A0
- Authority
- IL
- Israel
- Prior art keywords
- factor vii
- glycoforms
- vii glycoforms
- asparagine
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200001456 | 2000-10-02 | ||
DKPA200100262 | 2001-02-16 | ||
DKPA200100430 | 2001-03-14 | ||
DKPA200100751 | 2001-05-14 | ||
PCT/DK2001/000633 WO2002029025A2 (en) | 2000-10-02 | 2001-10-02 | Factor vii glycoforms |
Publications (1)
Publication Number | Publication Date |
---|---|
IL154879A0 true IL154879A0 (en) | 2003-10-31 |
Family
ID=27439823
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15488001A IL154880A0 (en) | 2000-10-02 | 2001-10-02 | Method for the production of vitamin k-dependent proteins |
IL15487901A IL154879A0 (en) | 2000-10-02 | 2001-10-02 | Factor vii glycoforms |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15488001A IL154880A0 (en) | 2000-10-02 | 2001-10-02 | Method for the production of vitamin k-dependent proteins |
Country Status (18)
Country | Link |
---|---|
US (6) | US6903069B2 (xx) |
EP (6) | EP1325147A2 (xx) |
JP (4) | JP4361730B2 (xx) |
KR (2) | KR100880624B1 (xx) |
CN (3) | CN1468303B (xx) |
AT (2) | ATE425254T1 (xx) |
AU (5) | AU9165201A (xx) |
BR (2) | BR0114374A (xx) |
CA (2) | CA2422216C (xx) |
CZ (1) | CZ2003718A3 (xx) |
DE (2) | DE60137950D1 (xx) |
ES (2) | ES2344887T3 (xx) |
HU (2) | HUP0301267A3 (xx) |
IL (2) | IL154880A0 (xx) |
MX (1) | MXPA03002853A (xx) |
NO (1) | NO20031471L (xx) |
PL (2) | PL361017A1 (xx) |
WO (4) | WO2002029045A2 (xx) |
Families Citing this family (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7786070B2 (en) | 1997-09-10 | 2010-08-31 | Novo Nordisk Healthcare A/G | Subcutaneous administration of coagulation factor VII |
US20050032690A1 (en) * | 1997-09-10 | 2005-02-10 | Rojkjaer Lisa Payne | Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia |
US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
PT1308455E (pt) | 1998-05-06 | 2006-08-31 | Genentech Inc | Composicao compreendendo anticorpos anti-her2 |
ATE428445T1 (de) * | 2000-02-11 | 2009-05-15 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
US7812132B2 (en) * | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
US20030040480A1 (en) * | 2001-07-20 | 2003-02-27 | Rasmus Rojkjaer | Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides |
DE60221553T2 (de) | 2001-10-02 | 2008-04-10 | Novo Nordisk Health Care Ag | Verfahren zur herstelllung rekombinanter proteine in eukaryontischen zellen |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
WO2004099231A2 (en) | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
AU2002351756A1 (en) | 2001-12-21 | 2003-07-15 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
KR20040065278A (ko) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | 변경된 인자 ⅶ 폴리펩티드의 액체 조성물 |
CA2483478A1 (en) * | 2002-04-30 | 2003-11-13 | Maxygen Holdings Ltd. | Factor vii or viia polypeptide variants |
US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
EP1517710B1 (en) * | 2002-06-21 | 2011-03-30 | Novo Nordisk Health Care AG | Pegylated factor vii glycoforms |
EP2283856B1 (en) * | 2002-06-21 | 2017-09-20 | Novo Nordisk Health Care AG | Stabilised solid compositions of factor VIIa polypeptides |
AU2003266931B2 (en) * | 2002-09-30 | 2010-01-21 | Bayer Healthcare Llc | FVII or FVIIa variants having increased clotting activity |
WO2004083421A1 (en) * | 2003-03-18 | 2004-09-30 | Novo Nordisk Health Care Ag | Method for the production of gla-residue containing serine proteases |
WO2004082708A2 (en) * | 2003-03-18 | 2004-09-30 | Novo Nordisk Health Care Ag | Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides |
US7771996B2 (en) * | 2003-03-20 | 2010-08-10 | Bayer Healthcare Llc | FVII or FVIIa variants |
US7897734B2 (en) | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
WO2006127896A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated factor ix |
MXPA05012476A (es) * | 2003-05-23 | 2006-02-22 | Novo Nordisk Healthcare Ag | Estabilizacion de proteina en solucion. |
DK1644504T3 (da) * | 2003-06-19 | 2010-05-25 | Bayer Healthcare Llc | Faktor VII- eller -VIIA-Gla-domænevarianter |
WO2004112828A1 (en) * | 2003-06-25 | 2004-12-29 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
US7687478B2 (en) * | 2003-06-30 | 2010-03-30 | Otsuka Chemical Co., Ltd. | Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same |
DE602004023848D1 (de) * | 2003-07-01 | 2009-12-10 | Novo Nordisk Healthcare Ag | Von factor vii polypeptiden |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
BRPI0413518A (pt) * | 2003-08-14 | 2006-10-10 | Novo Nordisk Healthcare Ag | composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético |
ES2381110T3 (es) | 2003-09-09 | 2012-05-23 | Novo Nordisk Health Care Ag | Polipéptidos de factor VII de coagulación |
AU2004275828B2 (en) | 2003-09-23 | 2010-04-29 | University Of North Carolina At Chapel Hill | Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage |
WO2005035748A1 (en) | 2003-10-10 | 2005-04-21 | Novo Nordisk Health Care Ag | Method for large-scale production of a polypeptide in eukaryote cells and a culture vessel suitable therefor |
CA2542017A1 (en) | 2003-10-14 | 2005-05-06 | Baxter International, Inc. | Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives |
GB0324044D0 (en) * | 2003-10-14 | 2003-11-19 | Astrazeneca Ab | Protein |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
WO2005054275A2 (en) | 2003-12-01 | 2005-06-16 | Novo Nordisk Health Care Ag | Nanofiltration of factor vii solutions to remove virus |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
TR201809670T4 (tr) * | 2003-12-19 | 2018-07-23 | Novo Nordisk Healthcare Ag | Faktör VII polipeptitlerinin stabilize edilmiş kompozisyonları. |
WO2005068620A1 (en) * | 2004-01-07 | 2005-07-28 | Novo Nordisk Health Care Ag | Method for the production of recombinant proteins |
AU2005243427B2 (en) | 2004-05-04 | 2010-07-22 | Novo Nordisk Health Care Ag | O-linked glycoforms of polypeptides and method to manufacture them |
KR20070043051A (ko) * | 2004-08-17 | 2007-04-24 | 쳇엘베 베링 게엠베하 | 변형된 비타민 k 의존적 폴리펩타이드 |
WO2006035060A2 (en) * | 2004-09-29 | 2006-04-06 | Novo Nordisk Health Care Ag | Purification of a bulk of a factor vii polypeptide by fractionated elution from an anion-exchange material |
EP1814573B1 (en) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
WO2006067116A1 (en) * | 2004-12-21 | 2006-06-29 | Novo Nordisk Health Care Ag | Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems |
JP2008525381A (ja) * | 2004-12-23 | 2008-07-17 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 関心のあるビタミンk依存性タンパク質を含んでなる組成物中におけるタンパク質混入物の量の減少 |
CA2593682C (en) | 2005-01-10 | 2016-03-22 | Neose Technologies, Inc. | Glycopegylated granulocyte colony stimulating factor |
ES2380485T3 (es) * | 2005-02-11 | 2012-05-14 | Novo Nordisk Health Care Ag | Producción de un polipéptido en un lÃquido de cultivo sin suero con hidrolizado de proteÃnas vegetales |
WO2006089613A1 (en) | 2005-02-28 | 2006-08-31 | Baxter International Inc. | Recombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k dependent protein expression |
JP2008532544A (ja) | 2005-03-15 | 2008-08-21 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 活性ビタミンk依存性タンパク質を生産するための方法及び組成物 |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
CN101198696B (zh) * | 2005-04-13 | 2014-02-26 | 阿斯利康(瑞典)有限公司 | 包含产生需要γ-羧化的蛋白质用的载体的宿主细胞 |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
PL1969127T5 (pl) * | 2005-12-21 | 2018-02-28 | Cnj Holdings, Inc | Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
EP2004214B1 (en) | 2006-03-16 | 2012-11-07 | STELLARIS PHARMACEUTICALS Aps | Local treatment with factor vii |
KR101492422B1 (ko) * | 2006-04-11 | 2015-02-12 | 체에스엘 베링 게엠베하 | 치료용 폴리펩타이드의 생체내 회수율을 증가시키는 방법 |
FR2901707B1 (fr) | 2006-05-31 | 2017-09-29 | Lab Francais Du Fractionnement | Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis |
WO2008009635A2 (en) * | 2006-07-17 | 2008-01-24 | Novo Nordisk Health Care Ag | Factor viia analogues with increased activity for treating thrombocytopenia |
JP2009544327A (ja) | 2006-07-21 | 2009-12-17 | ノヴォ ノルディスク アー/エス | O−結合型グリコシル化配列によるペプチドのグリコシル化 |
FR2904558B1 (fr) * | 2006-08-01 | 2008-10-17 | Lab Francais Du Fractionnement | "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees" |
EP2054521A4 (en) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES |
JP5167449B2 (ja) * | 2006-11-07 | 2013-03-21 | 独立行政法人科学技術振興機構 | 直鎖状核酸分子懸架支持体、直鎖状核酸分子伸長方法および直鎖状核酸分子標本 |
CN103804489A (zh) * | 2006-12-15 | 2014-05-21 | 巴克斯特国际公司 | 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物 |
KR101542752B1 (ko) | 2006-12-22 | 2015-08-10 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 변형된 응고 인자 |
US20100143326A1 (en) * | 2007-01-03 | 2010-06-10 | Novo Nordisk Healthcare A/G | SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES |
KR20150064246A (ko) | 2007-04-03 | 2015-06-10 | 바이오제너릭스 게엠베하 | 글리코페길화 g―csf를 이용하는 치료 방법 |
EP2147096B1 (en) * | 2007-04-13 | 2015-03-25 | Catalyst Biosciences, Inc. | Modified factor VII polypeptides and uses thereof |
AU2014202989B2 (en) * | 2007-04-26 | 2016-07-07 | Aptevo Biotherapeutics Llc | Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same |
AU2016238889B2 (en) * | 2007-04-26 | 2019-06-27 | Aptevo Biotherapeutics Llc | Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same |
EP2517714A1 (en) * | 2007-04-26 | 2012-10-31 | Inspiration Biopharmaceuticals, Inc. | Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same |
ES2551123T3 (es) | 2007-06-12 | 2015-11-16 | Ratiopharm Gmbh | Proceso mejorado para la producción de azúcares de nucleótido |
US8206967B2 (en) | 2007-07-06 | 2012-06-26 | Medimmune Limited | Method for production of recombinant human thrombin |
EP2014299A1 (en) * | 2007-07-11 | 2009-01-14 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor VII |
US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
CN101952016A (zh) | 2007-12-28 | 2011-01-19 | 巴克斯特国际公司 | 重组vwf配方 |
CN101965200B (zh) | 2008-02-27 | 2013-06-19 | 诺沃-诺迪斯克有限公司 | 缀合的因子ⅷ分子 |
TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子vii多肽和其用途 |
AU2009307648C1 (en) | 2008-10-21 | 2016-12-08 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
WO2010056584A1 (en) * | 2008-11-12 | 2010-05-20 | Baxter International Inc. | Method of producing serum-free insulin-free factor vii |
JP5027106B2 (ja) * | 2008-12-25 | 2012-09-19 | 一般財団法人阪大微生物病研究会 | 日本脳炎ウイルス抗原 |
NZ597600A (en) | 2009-07-27 | 2014-05-30 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
TWI537006B (zh) | 2009-07-27 | 2016-06-11 | 巴克斯歐塔公司 | 凝血蛋白接合物 |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
RU2744370C2 (ru) | 2009-07-27 | 2021-03-05 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
US8580554B2 (en) | 2009-07-31 | 2013-11-12 | Baxter International Inc. | Method of producing a polypeptide or virus of interest in a continuous cell culture |
JP5851410B2 (ja) * | 2009-10-30 | 2016-02-03 | シーエヌジェイ ホールディングス、インク. | 組換えビタミンk依存性タンパク質の生成法 |
EP2507627A2 (en) * | 2009-12-04 | 2012-10-10 | Momenta Pharmaceuticals, Inc. | Antennary fucosylation in glycoproteins from cho cells |
FR2954349A1 (fr) | 2009-12-22 | 2011-06-24 | Agronomique Inst Nat Rech | Sulfatase modifiant selectivement les glycosaminoglycanes |
WO2012075138A1 (en) * | 2010-11-30 | 2012-06-07 | Progenetics Llc | Method of producing biologically active vitamin k dependent proteins in transgenic animals |
EP2655607A4 (en) | 2010-12-21 | 2014-05-14 | Univ North Carolina | METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS |
CA2822591C (en) | 2010-12-22 | 2020-12-29 | Baxter International Inc. | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
US9505833B2 (en) | 2012-04-20 | 2016-11-29 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
WO2014057068A1 (en) | 2012-10-10 | 2014-04-17 | Novo Nordisk Health Care Ag | Liquid pharmaceutical composition of factor vii polypeptide |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
FR3006591B1 (fr) | 2013-06-11 | 2016-05-06 | Lab Francais Du Fractionnement | Composition de facteur vii presentant un point isoelectrique substantiellement homogene |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
WO2015158696A1 (en) * | 2014-04-16 | 2015-10-22 | Cmc Biologics A/S | A high cell density fill and draw fermentation process |
MX2016015944A (es) * | 2014-06-04 | 2017-08-15 | Amgen Inc | Metodos para cosechar cultivos de celulas de mamifero. |
US9714302B2 (en) | 2014-10-10 | 2017-07-25 | W. R. Grace & Co.—Conn. | Process for preparing spherical polymerization catalyst components for use in olefin polymerizations |
FR3034669B1 (fr) | 2015-04-07 | 2020-02-14 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Nouvelle utilisation du facteur von willebrand |
BR102015012334A2 (pt) | 2015-05-27 | 2016-11-29 | Fundação Hemoct De Ribeirão Preto Fundherp | processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea |
AR105669A1 (es) * | 2015-08-10 | 2017-10-25 | Glycotope Gmbh | Factor vii recombinante mejorado |
ES2803773T3 (es) * | 2015-12-02 | 2021-01-29 | CSL Behring Lengnau AG | Medios mejorados para la expresión de proteínas recombinantes dependientes de vitamina k |
EP3488858A1 (en) | 2017-11-27 | 2019-05-29 | Laboratoire Français du Fractionnement et des Biotechnologies | A von willebrand factor composition for use in treating a pathology mediated by angiogenesis |
US20210069306A1 (en) | 2019-08-15 | 2021-03-11 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4189534A (en) * | 1976-11-11 | 1980-02-19 | Massachusetts Institute Of Technology | Cell culture microcarriers |
US4357422A (en) * | 1980-08-14 | 1982-11-02 | Massachusetts Institute Of Technology | Method of enhancing interferon production |
US4335215A (en) * | 1980-08-27 | 1982-06-15 | Monsanto Company | Method of growing anchorage-dependent cells |
US4456591A (en) | 1981-06-25 | 1984-06-26 | Baxter Travenol Laboratories, Inc. | Therapeutic method for activating factor VII |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4664912A (en) * | 1984-10-01 | 1987-05-12 | Wiktor Tadeusz J | Process for the large scale production of rabies vaccine |
US4978616A (en) * | 1985-02-28 | 1990-12-18 | Verax Corporation | Fluidized cell cultivation process |
GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
US4975282A (en) | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
SE464816B (sv) * | 1985-10-15 | 1991-06-17 | Nilsson Kjell | Makroporoesa partiklar, foerfarande foer dess framstaellning och dess anvaendning |
GB2184759B (en) | 1985-12-28 | 1990-07-18 | Shimizu Construction Co Ltd | Concrete-filled tubular steel piece, concrete-filled steel tube column and method of constructing same. |
US5595886A (en) * | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US5576194A (en) * | 1986-07-11 | 1996-11-19 | Bayer Corporation | Recombinant protein production |
JPH01502080A (ja) | 1986-11-17 | 1989-07-27 | ニュー・イングランド・メディカル・センター | 組み換えビタミンk依存性蛋白質のガンマカルボキシル化の増強 |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5580560A (en) | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
WO1992001795A1 (en) * | 1990-07-23 | 1992-02-06 | Zymogenetics, Inc. | Gamma-carboxylase and methods of use |
EP0785273A1 (en) * | 1990-11-26 | 1997-07-23 | Genetics Institute, Inc. | Paired basic amino acid converting enzyme and DNA sequence encoding it |
US5965789A (en) * | 1991-01-11 | 1999-10-12 | American Red Cross | Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals |
DE69233398D1 (de) | 1991-02-28 | 2004-09-16 | Novo Nordisk As | Modifizierter faktor-vii |
US5997864A (en) | 1995-06-07 | 1999-12-07 | Novo Nordisk A/S | Modified factor VII |
US5661008A (en) * | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
US5268275A (en) * | 1991-05-08 | 1993-12-07 | The University Of North Carolina At Chapel Hill | Vitamin K-dependent carboxylase |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
IL104385A (en) * | 1992-01-17 | 1995-12-31 | Applied Research Systems | Method and device for growing biomass particles |
DK53792D0 (da) * | 1992-04-24 | 1992-04-24 | Novo Nordisk As | Fremgangsmaade til fremstilling af proteiner |
WO1993022448A1 (en) * | 1992-05-01 | 1993-11-11 | Teijin Limited | Fed batch culture method for protein secreting cells |
DE4221863C2 (de) | 1992-07-03 | 1997-04-17 | Stockhausen Chem Fab Gmbh | Copolymere der Allyliminodiessigsäure mit ungesättigten Carbonsäuren und deren Verwendung als Komplexbildner, Peroxidstabilisatoren, Builder in Wasch- und Reinigungsmitteln und Dispergatoren |
US5510328A (en) * | 1994-04-28 | 1996-04-23 | La Jolla Cancer Research Foundation | Compositions that inhibit wound contraction and methods of using same |
WO1998004680A1 (en) * | 1996-07-26 | 1998-02-05 | University Of Manitoba | Serum-free medium for growth of anchorage-dependant mammalian cells |
WO1998044942A1 (de) * | 1997-04-08 | 1998-10-15 | Baxter Aktiengesellschaft | Immuntolerante prothrombinkomplex-präparation |
AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
US6475725B1 (en) * | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
WO2000028065A1 (en) * | 1998-11-06 | 2000-05-18 | Novo Nordisk A/S | Method for the production of fvii |
WO2000054787A1 (en) | 1999-03-16 | 2000-09-21 | The Children's Hospital Of Philadelphia | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
ATE330003T1 (de) * | 1999-08-05 | 2006-07-15 | Baxter Ag | Rekombinanter stabiler zellklon, seine herstellung und verwendung |
UA74557C2 (en) * | 1999-09-03 | 2006-01-16 | Applied Research Systems | A method for producing a heterologous secreted protein from chinese hamster ovaries cells grown on microcarriers |
CA2406725C (en) * | 2000-04-26 | 2013-01-15 | Aventis Pharma Deutschland Gmbh | Edg8 receptor, its preparation and use |
-
2001
- 2001-10-02 WO PCT/DK2001/000635 patent/WO2002029045A2/en active Application Filing
- 2001-10-02 KR KR1020037004725A patent/KR100880624B1/ko not_active IP Right Cessation
- 2001-10-02 US US09/969,357 patent/US6903069B2/en not_active Expired - Lifetime
- 2001-10-02 JP JP2002532615A patent/JP4361730B2/ja not_active Expired - Fee Related
- 2001-10-02 BR BR0114374-3A patent/BR0114374A/pt not_active Application Discontinuation
- 2001-10-02 ES ES01971734T patent/ES2344887T3/es not_active Expired - Lifetime
- 2001-10-02 AU AU9165201A patent/AU9165201A/xx active Pending
- 2001-10-02 CZ CZ2003718A patent/CZ2003718A3/cs unknown
- 2001-10-02 CA CA2422216A patent/CA2422216C/en not_active Expired - Fee Related
- 2001-10-02 AU AU2001291653A patent/AU2001291653A1/en not_active Abandoned
- 2001-10-02 JP JP2002532595A patent/JP4477299B2/ja not_active Expired - Fee Related
- 2001-10-02 JP JP2002532652A patent/JP2004510439A/ja active Pending
- 2001-10-02 MX MXPA03002853A patent/MXPA03002853A/es not_active Application Discontinuation
- 2001-10-02 DE DE60137950T patent/DE60137950D1/de not_active Expired - Lifetime
- 2001-10-02 CN CN018167462A patent/CN1468303B/zh not_active Expired - Fee Related
- 2001-10-02 AT AT01976037T patent/ATE425254T1/de not_active IP Right Cessation
- 2001-10-02 IL IL15488001A patent/IL154880A0/xx unknown
- 2001-10-02 AU AU2001291651A patent/AU2001291651A1/en not_active Abandoned
- 2001-10-02 AU AU2001291652A patent/AU2001291652B2/en not_active Ceased
- 2001-10-02 WO PCT/DK2001/000634 patent/WO2002029084A2/en active Application Filing
- 2001-10-02 WO PCT/DK2001/000632 patent/WO2002029083A2/en active Application Filing
- 2001-10-02 AT AT01971734T patent/ATE465253T1/de active
- 2001-10-02 DE DE60141908T patent/DE60141908D1/de not_active Expired - Lifetime
- 2001-10-02 US US10/398,422 patent/US8202973B2/en not_active Expired - Fee Related
- 2001-10-02 CA CA002422214A patent/CA2422214A1/en not_active Abandoned
- 2001-10-02 HU HU0301267A patent/HUP0301267A3/hu unknown
- 2001-10-02 EP EP01971735A patent/EP1325147A2/en not_active Withdrawn
- 2001-10-02 HU HU0301245A patent/HUP0301245A3/hu unknown
- 2001-10-02 CN CN201210226379.9A patent/CN102766668B/zh not_active Expired - Fee Related
- 2001-10-02 CN CNA018166423A patent/CN1481438A/zh active Pending
- 2001-10-02 AU AU2001295431A patent/AU2001295431A1/en not_active Abandoned
- 2001-10-02 EP EP10003073A patent/EP2261330A1/en not_active Withdrawn
- 2001-10-02 EP EP01976037A patent/EP1325127B1/en not_active Expired - Lifetime
- 2001-10-02 BR BR0114373-5A patent/BR0114373A/pt not_active IP Right Cessation
- 2001-10-02 ES ES01976037T patent/ES2323761T3/es not_active Expired - Lifetime
- 2001-10-02 EP EP10010149A patent/EP2311943A3/en not_active Withdrawn
- 2001-10-02 KR KR1020037004723A patent/KR100861470B1/ko not_active IP Right Cessation
- 2001-10-02 PL PL01361017A patent/PL361017A1/xx not_active Application Discontinuation
- 2001-10-02 JP JP2002532653A patent/JP2004512835A/ja active Pending
- 2001-10-02 US US09/969,358 patent/US20020151471A1/en not_active Abandoned
- 2001-10-02 PL PL01361058A patent/PL361058A1/xx not_active Application Discontinuation
- 2001-10-02 IL IL15487901A patent/IL154879A0/xx unknown
- 2001-10-02 EP EP01971734A patent/EP1325113B1/en not_active Revoked
- 2001-10-02 WO PCT/DK2001/000633 patent/WO2002029025A2/en active Application Filing
- 2001-10-02 EP EP01971733A patent/EP1356074A2/en not_active Withdrawn
-
2003
- 2003-04-01 NO NO20031471A patent/NO20031471L/no not_active Application Discontinuation
- 2003-12-02 US US10/725,843 patent/US20050075289A1/en not_active Abandoned
-
2006
- 2006-12-21 US US11/643,607 patent/US20070122884A1/en not_active Abandoned
-
2009
- 2009-07-15 US US12/503,498 patent/US20090281022A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL154879A0 (en) | Factor vii glycoforms | |
AU5822801A (en) | Tharmaceutical composition comprising a factor viia and a factor xiii | |
AU2002351343A8 (en) | Absorbent garment tab having elasticity zones | |
AU2002361902A8 (en) | Hemostatic compositions and methods for controlling bleeding | |
HK1065925A1 (en) | Infant formula compositions comprising increased amounts of alpha- lactalbumin | |
IL159030A0 (en) | Process for the preparation of prostaglandins and analogues thereof | |
PL371464A1 (en) | 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them | |
IL154422A0 (en) | Paroxetine compositions and processes for making the same | |
HK1071677A1 (en) | Process for producing food additive composition and food compositions containing the same | |
DK1051962T3 (da) | Tandplejemiddel indeholdende perlit | |
AU2001262759A1 (en) | Infant's chamber pot having health checking function | |
EP1402871A4 (en) | ANTITROMOMBOTIC COMPOSITIONS AND MEDICAL INSTRUMENTS CONTAINING THEM | |
IL161261A0 (en) | Storage-stable fibrinogen solutions | |
MXPA03007549A (es) | Composiciones hidrofobicas de reologia modificada, novedosas, agentes de modificacion y metodos de fabricacion. | |
AU6913600A (en) | Transgenic prothrombin and related thrombin precursors and transgenics, methods,compositions, uses and the like relating thereto | |
ZA200105452B (en) | Compositions for the treatment of malaria. | |
IT1304174B1 (it) | Composizioni perossidiche | |
GB0114350D0 (en) | "Napkin" modification | |
GB0104947D0 (en) | Composition comprising elevated levels of a component polymer | |
AU2277P (en) | White Delight Solanum tuberosum | |
AU2002334756A1 (en) | Automatic digitization of garment patterns | |
TW519266U (en) | Improved circuit of semi-optical mouse | |
HU0100593D0 (en) | Cherie variety of potato (solanum tuberosum l.) | |
HUP0100594A2 (en) | Juliette variety of potato (solanum tuberosum l.) | |
AU2002327173A1 (en) | Nanocomposite containing platelet and fibrous nano-filler |